Cargando…

Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms

BACKGROUND: Patient-reported outcome (PRO) measures have been shown to be effective for tracking treatment outcomes in multiple sclerosis (MS). However, collecting PROs as part of the clinical standard of care can be time-consuming and examination of their validity for use in an MS sample has been l...

Descripción completa

Detalles Bibliográficos
Autores principales: Medina, Luis D, Torres, Stephanie, Alvarez, Enrique, Valdez, Brooke, Nair, Kavita V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882038/
https://www.ncbi.nlm.nih.gov/pubmed/31819803
http://dx.doi.org/10.1177/2055217319885986
_version_ 1783474068272447488
author Medina, Luis D
Torres, Stephanie
Alvarez, Enrique
Valdez, Brooke
Nair, Kavita V
author_facet Medina, Luis D
Torres, Stephanie
Alvarez, Enrique
Valdez, Brooke
Nair, Kavita V
author_sort Medina, Luis D
collection PubMed
description BACKGROUND: Patient-reported outcome (PRO) measures have been shown to be effective for tracking treatment outcomes in multiple sclerosis (MS). However, collecting PROs as part of the clinical standard of care can be time-consuming and examination of their validity for use in an MS sample has been limited. OBJECTIVE: To determine the discriminant validity of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms in a real-world MS clinic population. DESIGN/METHODS: Neuro-QoL is a series of questionnaires for tracking physical function, emotional/cognitive health, and social abilities in clinical populations. Neuro-QoL data from 902 MS patients were analyzed for psychometric properties and factor structure. RESULTS: Neuro-QoL demonstrated acceptable reliability in the moderate-to-good ranges. Moderate support for convergent validity was observed with other measures of MS quality of life, disease severity, and symptoms. However, results from a confirmatory factor analysis suggested poor model fit for most of the 12 domains tested. CONCLUSIONS: These findings support the utility of some of the Neuro-QoL questionnaires in evaluating MS-related PROs. However, additional research may help abridge and strengthen these measures for use in this population.
format Online
Article
Text
id pubmed-6882038
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-68820382019-12-09 Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms Medina, Luis D Torres, Stephanie Alvarez, Enrique Valdez, Brooke Nair, Kavita V Mult Scler J Exp Transl Clin Original Research Paper BACKGROUND: Patient-reported outcome (PRO) measures have been shown to be effective for tracking treatment outcomes in multiple sclerosis (MS). However, collecting PROs as part of the clinical standard of care can be time-consuming and examination of their validity for use in an MS sample has been limited. OBJECTIVE: To determine the discriminant validity of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms in a real-world MS clinic population. DESIGN/METHODS: Neuro-QoL is a series of questionnaires for tracking physical function, emotional/cognitive health, and social abilities in clinical populations. Neuro-QoL data from 902 MS patients were analyzed for psychometric properties and factor structure. RESULTS: Neuro-QoL demonstrated acceptable reliability in the moderate-to-good ranges. Moderate support for convergent validity was observed with other measures of MS quality of life, disease severity, and symptoms. However, results from a confirmatory factor analysis suggested poor model fit for most of the 12 domains tested. CONCLUSIONS: These findings support the utility of some of the Neuro-QoL questionnaires in evaluating MS-related PROs. However, additional research may help abridge and strengthen these measures for use in this population. SAGE Publications 2019-11-26 /pmc/articles/PMC6882038/ /pubmed/31819803 http://dx.doi.org/10.1177/2055217319885986 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Paper
Medina, Luis D
Torres, Stephanie
Alvarez, Enrique
Valdez, Brooke
Nair, Kavita V
Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms
title Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms
title_full Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms
title_fullStr Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms
title_full_unstemmed Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms
title_short Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms
title_sort patient-reported outcomes in multiple sclerosis: validation of the quality of life in neurological disorders (neuro-qol™) short forms
topic Original Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882038/
https://www.ncbi.nlm.nih.gov/pubmed/31819803
http://dx.doi.org/10.1177/2055217319885986
work_keys_str_mv AT medinaluisd patientreportedoutcomesinmultiplesclerosisvalidationofthequalityoflifeinneurologicaldisordersneuroqolshortforms
AT torresstephanie patientreportedoutcomesinmultiplesclerosisvalidationofthequalityoflifeinneurologicaldisordersneuroqolshortforms
AT alvarezenrique patientreportedoutcomesinmultiplesclerosisvalidationofthequalityoflifeinneurologicaldisordersneuroqolshortforms
AT valdezbrooke patientreportedoutcomesinmultiplesclerosisvalidationofthequalityoflifeinneurologicaldisordersneuroqolshortforms
AT nairkavitav patientreportedoutcomesinmultiplesclerosisvalidationofthequalityoflifeinneurologicaldisordersneuroqolshortforms